These radio-labeled Amatuximab complexes were tested in a pancreatic cancer xenograft model, showing MSLN-specific accumulation and a significant reduction in tumor mass, accompanied by overall toxicity [145]. This evidence concerns the gene MSLN and pancreatic neoplasm.